Merck (MRK) announced the initiation of the MOBILIZE-1 Phase 3 clinical trial evaluating the safety, immunogenicity and efficacy of a single dose of V181, an investigational quadrivalent vaccine, for the prevention of dengue disease caused by any of the four dengue virus serotypes, regardless of prior dengue exposure. Recruitment for the trial has begun, and the first participants are now enrolling in Singapore. The primary endpoints of the study are safety and efficacy of a single dose of V181 in preventing symptomatic virologically confirmed dengue (VCD) of any severity, due to any of the four dengue serotypes, regardless of prior dengue exposure.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- RFK Jr. names eight members to vaccine panel, WSJ reports
- RFK Jr. names new CDC vaccine advisory panel picks, STAT reports
- Merck & Company: Strategic Positioning and Innovation Drive Buy Rating
- Trump Trade: RFK Jr. removes members of vaccine-advising CDC panel
- Cautious Hold Rating on Merck’s Enlicitide Amid Promising Trial Results and Market Uncertainties
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue